Rapport Therapeutics reported that a post‑hoc analysis of its Phase 2a trial of RAP‑219 in drug‑resistant focal‑onset seizures was presented at the 2025 American Epilepsy Society Annual Meeting. The analysis, based on 30 patients with implanted NeuroPace RNS systems, shows a 77.8 % reduction in clinical seizures compared with baseline (p = 0.01) and a 24 % seizure‑free rate over an 8‑week treatment period (p < 0.0001). The study also documents consistent median response and early onset of action, with significant improvements in seizure severity and daily functioning measured by the Seizure Severity Response Questionnaire.
The use of the NeuroPace responsive neurostimulation system provided objective, continuous seizure monitoring, allowing the trial to capture both long and brief events. Early onset of efficacy and a stable median response across the 8‑week period suggest that RAP‑219’s TARPγ8‑specific AMPA receptor modulation delivers rapid, sustained seizure control—an important attribute for patients with refractory epilepsy.
These results reinforce Rapport’s strategy to advance RAP‑219 into two pivotal Phase 3 trials scheduled for the third quarter of 2026. The company also plans an end‑of‑Phase 2 meeting with the U.S. Food and Drug Administration this quarter. In addition to epilepsy, Rapport is expanding the pipeline to bipolar disorder and diabetic peripheral neuropathic pain, positioning RAP‑219 as a potential first‑in‑class, precision‑neuroscience therapy with broad therapeutic reach.
Investors have responded positively to the data, reflecting confidence in RAP‑219’s clinical trajectory and the company’s precision‑targeted approach. The strong efficacy profile aligns with the unmet need in epilepsy, where up to 40 % of patients continue to experience seizures despite existing therapies.
Chief Medical Officer Jeffrey Sevigny said the new data “reinforce the company’s position to advance RAP‑219 into pivotal Phase 3 trials.” Earlier comments from CEO Abe Ceesay highlighted that the topline results “greatly exceeded expectations on all efficacy measures,” underscoring management’s optimism about the drug’s potential.
The post‑hoc analysis underscores RAP‑219’s promise as a blockbuster antiseizure medication. By targeting the TARPγ8 subunit, the drug offers a focused mechanism that may reduce side‑effects compared with broader‑acting agents, potentially improving patient adherence and market adoption in a highly competitive epilepsy landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.